stockrowEnanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024.
- Revenue
- −21.6%
- EPS
- +21.2%
- Free cash flow
- −157.5%
Quarter to June 2026, against a year earlier
Follow ENTA
Alert me
Enanta Pharmaceuticals, Inc. (ENTA) EV/Sales
As of 6 November 2026, Enanta Pharmaceuticals, Inc. (ENTA) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −2.5× (November 2023) to 17.7× (November 2021); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | — |
| FY2024 | −0.4× | — |
| FY2023 | −1.9× | — |
| FY2022 | 9.5× | 2.36% |
| FY2021 | 9.3× | 116.25% |
| FY2020 | 4.3× | 4.79% |
| FY2019 | 4.1× | (35.37%) |
| FY2018 | 6.3× | (4.55%) |
| FY2017 | 6.6× | 99.80% |
| FY2016 | 3.3× | 1.04% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.6× | 22.58% |
| Mar 2026 | 2.9× | (26.56%) |
| Dec 2025 | 4.0× | 292.16% |
| Sep 2025 | 1.0× | — |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.4× |
| SCTX Scribe Therapeutics Inc. compare | n/m |
| KYTX Kyverna Therapeutics, Inc. compare | n/m |
| GALT Galectin Therapeutics Inc. compare | n/m |
| ENTA Enanta Pharmaceuticals, Inc. | 2.0× |
| AGEN Agenus Inc. compare | 3.2× |
| PRLD Prelude Therapeutics Incorporated compare | 9.0× |
| XFOR X4 Pharmaceuticals, Inc. compare | 17.0× |
| BNTC Benitec Biopharma Limited compare | 3,500× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)